A cell-free enantioselective transformation of the carbon atom of CO has never been reported. In the urgent context of transforming CO into products of high value, the enantiocontrolled synthesis of chiral compounds from CO would be highly desirable. Using an original hybrid chemoenzymatic catalytic process, we report herein the reductive oligomerization of CO into C (dihydroxyacetone, DHA) and C (l-erythrulose) carbohydrates, with perfect enantioselectivity of the latter chiral product. This was achieved with the key intermediacy of formaldehyde. CO is first reduced selectively by 4e by an iron-catalyzed hydroboration reaction, leading to the isolation and complete characterization of a new bis(boryl)acetal compound derived from dimesitylborane. In an aqueous buffer solution at 30 °C, this compound readily releases formaldehyde, which is then involved in selective enzymatic transformations, giving rise either (i) to DHA using a formolase (FLS) catalysis or (ii) to l-erythrulose with a cascade reaction combining FLS and d-fructose-6-phosphate aldolase (FSA) A129S variant. Finally, the nature of the synthesized products is noteworthy, since carbohydrates are of high interest for the chemical and pharmaceutical industries. The present results prove that the cell-free synthesis of carbohydrates from CO as a sustainable carbon source is a possible alternative pathway in addition to the intensely studied biomass extraction and syntheses from fossil resources.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jacs.1c07872DOI Listing

Publication Analysis

Top Keywords

reductive oligomerization
8
enantioselective reductive
4
oligomerization carbon
4
carbon dioxide
4
dioxide l-erythrulose
4
l-erythrulose chemoenzymatic
4
chemoenzymatic catalysis
4
catalysis cell-free
4
cell-free enantioselective
4
enantioselective transformation
4

Similar Publications

Securinega alkaloids, known for their unique structures and neuroplasticity-inducing potential, are promising candidates for treating neurodegenerative diseases such as depression and substance use disorders (SUD). Herein, we delineate the total synthesis of two dimeric Rauhut-Currier (RC) reaction-based securinega alkaloids, (-)-flueggenine A and (-)-15'--flueggenine D. The key step involved a novel reductive Heck dimerization strategy, utilizing a silyl-tethered enone coupling partner to ensure the desired reactivity and stereoselectivity.

View Article and Find Full Text PDF

Targeted protein degradation with bifunctional molecules as a novel therapeutic modality for Alzheimer's disease & beyond.

Neurotherapeutics

December 2024

Department of Neurology, Precision Therapeutics Unit, Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. Electronic address:

Alzheimer's disease (AD) is associated with memory and cognitive impairment caused by progressive degeneration of neurons. The events leading to neuronal death are associated with the accumulation of aggregating proteins in neurons and glia of the affected brain regions, in particular extracellular deposition of amyloid plaques and intracellular formation of tau neurofibrillary tangles. Moreover, the accumulation of pathological tau proteoforms in the brain concurring with disease progression is a key feature of multiple neurodegenerative diseases, called tauopathies, like frontotemporal dementia (FTD) where autosomal dominant mutations in the tau encoding MAPT gene provide clear evidence of a causal role for tau dysfunction.

View Article and Find Full Text PDF
Article Synopsis
  • - Huntington's disease (HD) is a genetic neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin gene, leading to the accumulation of harmful mutant proteins in nerve cells.
  • - The NLRP3 inflammasome plays a crucial role in inflammation and its overactivation contributes to neurodegeneration in HD; inhibiting it showed potential benefits in mice by reducing toxic inflammation and neuronal damage.
  • - Antcin-H, a compound derived from the medicinal fungus Antrodia cinnamomea, was found to decrease neuroinflammation and toxicity while improving motor function and survival rates in a mouse model of HD, indicating its potential as a therapeutic option.
View Article and Find Full Text PDF

Nanoparticulate drug combination inhibits DNA damage repair and PD-L1 expression in BRCA-mutant and wild type triple-negative breast cancer.

J Control Release

January 2025

Advanced Pharmaceutics and Drug Delivery Laboratory, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto M5S 3M2, Ontario, Canada. Electronic address:

Article Synopsis
  • Metastatic breast cancer has a high mortality rate and is hard to treat, especially in triple-negative breast cancer (TNBC) due to factors like DNA repair and immunosuppression.
  • PARP inhibitors like olaparib can help, but problems like drug resistance and increased PD-L1 can limit their effectiveness.
  • The study tested a new treatment using specialized polymer-lipid nanoparticles carrying doxorubicin to target TNBC, showing better results in reducing tumor growth and metastasis compared to olaparib.
View Article and Find Full Text PDF
Article Synopsis
  • - The study explores how different molecular structures of multialkylated aromatic amides (MAAs), used as drag reducing agents (DRAs) in natural gas pipelines, impact energy efficiency and corrosion inhibition.
  • - Researchers synthesized MAAs with varying numbers of amide groups and dodecane chains, finding that the molecular structure significantly influences the agents' interfacial activity and film-forming properties on carbon steel surfaces.
  • - Results showed that MAAs with more amide groups and dodecane chains led to thicker and smoother films, enhancing corrosion inhibition and drag reduction rates—specifically, MAA-3 exhibited the highest performance among the synthesized surfactants.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!